BioSpace News Archive

Incyte announced the European Commission has approved Jakavi® for the treatment of patients aged 12 years and older with acute or chronic GVHD who have inadequate response to corticosteroids or other systemic therapies.

Reduced overall time to market investment in new drugs, access to expensive technologies, and greater flexibility are some advantages offered by biopharmaceutical manufacturing companies.

Albany NY, United States: Cystoscope is a medical device that has a thin tube with camera and a light source at the tip of device.

Albany NY, United States: Vaccines are biological products which stimulate the immune system of the body to protect the body against foreign substances.

Albany NY, United States: Neuropsychiatry refers to a branch of medicine that comprises the disciplines of both neurology and psychiatry and treatment of pathologies that involves both.

Albany NY, United States: Narcotic analgesic combination drugs are medicines that contain an opiate pain reliever, with at least one different analgesic such as acetaminophen or ibuprofen.

Albany NY, United States: Pouchitis is an inflammatory condition of the ileal pouch. It happens when the ileal pouch reservoir becomes inflamed or irritated.

QIAGEN N.V. announced that its NeuMoDx HSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 DNA and/or herpes simplex virus type 2 has received CE-IVD certification for the European Union and other countries that accept this marking.

Daiichi Sankyo and AstraZeneca’s ENHERTU® has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.

Captor Therapeutics S.A., a biopharmaceutical company focused on the development of targeted protein degradation drugs for cancer and autoimmune diseases, announces it will host a virtual Research and Development day on Wednesday 18 May 2022 at 10:00 am EDT.